Barr Pharmaceuticals, Inc. (NY:BRL)
66.75
-0 (-0%)
| Barr Pharmaceuticals, Inc. (NY:BRL) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $66.75 | 52 Week High | $68.35 | ||
| Open | $66.75 | 52 Week Low | $40.53 | ||
| Day High | $66.75 | P/E | 47.68 | ||
| Day Low | $66.75 | EPS | $1.40 | ||
| Volume | 27,546,384 | ||||
| More BRL Info: Chart SEC Filings Profile Historical Options | |||||
Barr Pharmaceuticals Inc. Summary
Barr Pharmaceuticals, Inc. engages in the development, manufacture, and marketing of generic and proprietary pharmaceuticals primarily in the area of female healthcare.
Executives
Bruce L. Downey - Chairman, CEO
Links
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| 5BQ | 6 | ||
Entities who have mentioned BRL
- Merrill Lynch | View Related Stories »
- JPMorgan | View Related Stories »
- David Moenning | View Related Stories »
- UBS | View Related Stories »
- Matrix USA | View Related Stories »
- Credit Suisse | View Related Stories »
- Morgan Stanley | View Related Stories »
- Wachovia | View Related Stories »
- Banc of America | View Related Stories »
- Goldman Sachs | View Related Stories »
- Bear Stearns | View Related Stories »
- Raymond James | View Related Stories »
- Bankruptcy | View Related Stories »
- KeyBanc | View Related Stories »
- Standard & Poor's | View Related Stories »
- Lehman Brothers | View Related Stories »
- Jefferies & Co | View Related Stories »
- Bain Capital | View Related Stories »
- Lazard | View Related Stories »
- Wellspring Capital Management | View Related Stories »
- Hellman & Friedman LLC | View Related Stories »
- American Technology Research | View Related Stories »
- Barclays | View Related Stories »
- Apollo Management | View Related Stories »
- Citi | View Related Stories »
View All Press ReleasesCompany Press Releases on BRL
- Bearclaw Announces Appointment of Director
- Bearclaw Announces Appointment of Director
- Bearclaw Announces Appointment of Director
- Bearclaw Announces Appointment of Director
- Bearclaw's President Dies Suddenly
StreetInsider Reports on BRL by Category
View All BlogsBlogs on BRL
- Genzyme: Near Term Sell, Long Term Buy
- Dr. Reddy's: Benefit from Obama and India with One Stock
- A Look at D.E. Shaw's Q408 Holdings: Just for Fun
- Eric Mindich's Eton Park Capital Likes Gold
- Moore Capital Investments: Theme Is Economic Recovery
Comments on recent BRL articles
Comments on BRL
No comments are currently available.
on Jan 2, 2009
at 03:04 PM Despite Lehman failure... Hats off to the Wall Street gurus who pulled off deals despite the carnage for example Teva's successful takeover of Barr was represented by Lehman until the venerable finance house went belly up. Nevertheless the deal close on time.
Article: Top 15 For 2008 (No. 14): M&A Wreckage
on May 8, 2008
at 02:02 PM brl great timing merrill lynch sAVED PEOPLE A FORTUNE BY DOWNGRADING AFTER THE FALL
Article: Merrill Lynch Downgrades Barr Pharmaceuticals (BRL) to Neutral